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Evaluation of a novel vital sign device to
reduce maternal mortality and morbidity in
low-resource settings: a mixed method
feasibility study for the CRADLE-3 trial
Nicola Vousden1* , Elodie Lawley1, Hannah L. Nathan1, Paul T. Seed1, Adrian Brown2, Tafadzwa Muchengwa4,
Umesh Charantimath3, Mrutyunjaya Bellad3, Muchabayiwa Francis Gidiri5, Shivaprasad Goudar3, Lucy C. Chappell1,
Jane Sandall1, Andrew H. Shennan1 and on behalf of the CRADLE Trial Collaborative Group
Abstract
Background: The CRADLE-3 trial is a stepped-wedge randomised controlled trial aiming to reduce maternal mortality
and morbidity by implementing a novel vital sign device (CRADLE Vital Sign Alert) and training package into routine
maternity care in 10 low-income sites. The MRC Guidance on complex interventions proposes that interventions and
implementation strategies be shaped by early phase piloting and development work. We present the findings of a
three-month mixed-methodology feasibility study for this trial, describe how this was informed by the MRC guidance
and the study design was refined.
Methods: The fidelity, dose, feasibility and acceptability of implementation and training materials were assessed in
three representative non-trial sites (Zimbabwe, Ethiopia, India) using multiple-choice questionnaires, evaluation of
clinical management (action log), healthcare provider (HCP) semi-structured interviews and focus groups 4–10 weeks
after implementation. Simultaneously, the 10 sites included in the main trial (eight countries) collected
primary outcome data to inform the power calculation and randomisation allocation and assess the
feasibility of data collection.
Results: The package was implemented with high fidelity (85% of HCP trained, n = 204). The questionnaires indicated
a good understanding of device use with 75% of participants scoring > 75% (n = 97; 90% of those distributed). Action
logs were inconsistently completed but indicated that the majority of HCP responded appropriately to abnormal
results. From 18 HCP interviews and two focus groups it was widely reported that the intervention improved capacity
to make clinical decisions, escalate care and make appropriate referrals. Nine of the ten main trial sites achieved ethical
approval for pilot data collection. Intensive care was an inconsistent marker of morbidity and stroke an infrequent
outcome and therefore they were removed from the main trial composite outcome. Tools and methods of data
collection were optimized and event rates used to inform randomisation.
Conclusions: This feasibility study demonstrates that the components of the intervention were acceptable, methods of
implementing were successful and the main trial design would be feasible. Qualitative work identified key moderators
that informed the main trial process evaluation. Changes to the training package, implementation strategy, study design
and processes were identified to refine the implementation in the main trial.
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Background
Maternal mortality remains a challenge in the post-
Millennium Development Goal (MDG) era, especially in
low resource settings where in 2013, 800 women died
every day from complications of pregnancy and childbirth
[1]. The most common causes of maternal mortality
worldwide are hypertensive disorders, obstetric haemor-
rhage, sepsis and abortion complications. There are simple
interventions that are readily available to treat these
conditions. However, in low-resource settings, delays in
presenting to care, reaching care and receiving this care
all contribute to high maternal mortality. Measurement of
vital signs is the first step in recognising women at risk of
deterioration and therefore in initiating life-saving treat-
ments [2]. Despite this, access to accurate equipment to
measure vital signs and adequate healthcare provider
(HCP) training on escalation pathways are frequently lack-
ing in low and middle income countries (LMIC) [3].
The CRADLE-3 trial aims to determine whether imple-
mentation of a novel vital sign alert (VSA) device into rou-
tine maternity care at both community and facility levels,
will reduce a composite outcome of maternal mortality and
morbidity in LMIC. This is a stepped wedge randomised
controlled trial (RCT) based in seven low-income and one
middle-income country over 20 months. The CRADLE
VSA is a semi automated device that measures blood pres-
sure, pulse and calculates the mothers risk of shock. It has
been extensively validated for accuracy [4, 5] and usability
[6] and the need defined in this context through field work
and stakeholder engagement.
The trial development was informed by the Medical
Research Council (MRC) guidance for complex interven-
tions [7]. Although the stages of development and evalu-
ation can take many different forms, it is recommended
that key uncertainties in the design are systematically
studied in a development phase. Procedures should be
tested for their acceptability and the likely rates of
recruitment estimated to inform sample size calcula-
tions. The guidance also states that a mixture of qualita-
tive and quantitative methods is likely to be needed in
order to understand barriers to participation and esti-
mated responses. Guidance on how best to undertake
this was provided by Moore et al. in 2015 [8].
Whilst the MRC guidance is heavily cited there are few
published papers that consider its practical application dur-
ing this stage especially taking into context the challenges
of working in multiple LMIC. Prior to the CRADLE 3 trial
start a mixed-methodology feasibility study was undertaken
to finalise the intervention and implementation processes
which were guided by the Expert Recommendations for
Implementing Change (ERIC) project [9]. Potential causal
mechanisms and contextual factors that may influence the
success of the trial were also identified. A logic model was
created to describe these components and to identify the
key research questions that inform the process evaluation
of the main trial [10]. Through presenting results of this
feasibility study, we aim to provide a worked example of
the application of the MRC guidance in finalising the subse-
quent trial protocol and process evaluation.
Method
The study took place over 3 months from November
2015 to January 2016 with a further 3 months to analyse
and adapt the intervention and protocol prior to the trial
start in April 2016. It consisted of three key objectives:
1. Exploration of the acceptability and feasibility of the
CRADLE programme components and the
development of its implementation strategies by a
mixed-method evaluation in three non-trial sites
representative of the 10 main trial clusters.
2. Collection of primary outcome data in the 10 main
trial clusters in order to evaluate the methods of
data collection, and assess factors related to the
randomisation programme (number of deliveries
per month) and the sample size calculation.
3. Utilise results to optimize final CRADLE 3 protocol
including training materials and implementation
strategy for main trial.
Setting
Implementation was undertaken in three areas representa-
tive of the main trial clusters. These were a convenience
sample of facilities meeting the study’s inclusion criteria
but geographically distant to avoid contamination of the
main trial. All facilities approached agreed to participate.
These were sites based around Ramdurg in Karnataka,
India, Bishoftu in Ethiopia, and Masvingo in Zimbabwe.
In accordance with the 10 main trial clusters (list in
Additional file 1) these included one or more secondary
or tertiary facilities that provided comprehensive emer-
gency obstetric care and the surrounding primary care
facilities that referred to these higher facilities and were
urban or semi-urban.
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Participants
The CRADLE VSA was incorporated into routine mater-
nity care. All HCPs working in these services were
eligible for training and all women identified as pregnant
or within the 6 weeks post-partum period, presenting
for antenatal, intrapartum or postpartum care within the
three areas were eligible for inclusion.
Intervention
The intervention, described in accordance with the TiDieR
guidance [11], included two key components. The Microlife
CRADLE VSA is a novel device that accurately measures
blood pressure and pulse [4, 5, 12] and calculates the preg-
nant mother’s risk of hypovolaemic or septic shock [13, 14].
It has been specifically developed to meet the World Health
Organisation’s criteria for use in a low resource setting. A
traffic light Early Warning System display alerts users to
abnormalities in the vital signs results. The lights are
triggered by standard thresholds of hypertension as well as
by shock index (heart rate divided by systolic blood pres-
sure) [13], as shown in Table 1. The CRADLE VSA was
incorporated into routine maternity care.
Primary, secondary and tertiary facilities were allo-
cated devices according to their delivery rate, staffing
numbers and number of beds per ward. Pre-existing
BP devices were removed from clinical areas, unless
existing equipment has functionality designed for that
area e.g. repeated automated measures in a high
dependency area. This was supported with a CRADLE
training package consisting of short animated film,
interactive sessions, booklet and posters. There were
two sets of training materials available, one for facility
HCP and one for community HCP with very limited
resources or no formal training.
The CRADLE package content covered:
 How to use the CRADLE VSA.
 Maintenance of the CRADLE VSA.
 Basic overview of clinical assessment and
management of pre-eclampsia/eclampsia and shock
in relation to the traffic light alerts.
The local implementation team and research team
delivered one-off interactive group training sessions
lasting 2–4 h to local stakeholders and representative
HCP from each of the clinical areas in the cluster.
This included a presentation on the background of the
CRADLE VSA and the importance of measuring vital
signs in pregnancy. This was followed by a demonstration
of the features and use of the CRADLE VSA and small
group practice using the CRADLE VSA. Training finished
with interactive clinical scenarios exploring the use of the
CRADLE VSA with available guidance and resources.
Attendees were given training materials and CRADLE
VSA devices to disseminate to their clinical areas. The
implementation team attended each clinical area over
the subsequent days (depending on cluster size) to sup-
port dissemination and hold interactive sessions.
The core components of the intervention (provision of
the CRADLE VSA devices, animated films, posters and
content of the training presentation) were standardized
across all sites. The way the core components were
delivered was adapted to meet the needs of the site. This
intervention can be described as complex [7] because it
comprises multiple interacting components that require
considerable shift in the behavior of recipients. It is also
being implemented at multiple levels of low-resource
health services and will affect multiple outcome mea-
sures [7]. In the main trial, the intervention will be com-
pared to routine maternity care with clinical assessment
and management according to local guidelines. Vital
signs measurement is normally undertaken with a variety
of blood pressure devices where these are available,
which are rarely validated in pregnancy.
Study design
For this feasibility study, the 10 clusters involved in the
main trial collected the primary outcome as defined at
that time: a composite of maternal mortality or major
morbidity (one of maternal death, Intensive Care Unit
admission (or predefined equivalent), eclampsia, stroke,
or hysterectomy, with no double counting). Data were
collected from existing healthcare facility registers, ma-
ternity records, maternal mortality reports and health-
care providers at the discretion of the local research
team. Anonymised data were recorded onto a paper
form and transferred by the research team onto a
purpose-built online database (MedSciNet).







RED LIGHT & UP
ARROW
Severe hypertension ≥ 160 and / or ≥ 110
YELLOW LIGHT &
UP ARROW
Hypertension ≥ 140 & ≤ 159 and /
or ≥ 90 &≤ 109
GREEN LIGHT Normal < 140 and < 90
Shock Index (SI) Thresholds
Light and Arrow
Results
Category Shock Index (HR /
sBP)
RED LIGHT & DOWN
ARROW
Severe shock ≥ 1.7
YELLOW LIGHT &
DOWN ARROW
Shock ≥ 0.9 and < 1.7
GREEN LIGHT Normal < 0.9
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The components of the mixed methodology assess-
ment of the acceptability and feasibility of the CRADLE
programme components, undertaken in the three non-
trial sites are shown in Table 2.
In order to explore potential mediators of action a pur-
posive sample of HCP were requested to complete action
logs of clinical practice to evaluate their referral practice. In
these action logs, HCP were requested to record any “yel-
low” or “red” Early Warning System with the action they
took, for example ‘administered anti-hypertensives and
referred to hospital today’. This was compared to baseline
information of available resources to interpret how HCP
had understood and interpreted the training. Question-
naires assessing knowledge of when and how to use the
CRADLE VSA and how to interpret the results were filled
after training by a random sample of participants.
We undertook semi-structured interviews and focus
groups (guides available on request) 4–10 weeks after
implementation. This time was selected to allow suffi-
cient experience of the VSA in clinical practice whilst
allowing time to make improvements to the intervention
within the funding timeline. The aim of these was to
further knowledge on the acceptability of the device
features gained from a previous observational study of
the CRADLE VSA (CRADLE 2) [15] by exploring the
feasibility of implementing the CRADLE package and
how incorporating it into routine care might change
behaviour. Participants were selected through purposive
sampling to ensure representation of different HCP
cadres in hospital and community care. Participants
were approached face-to-face and gave written informed
consent to participate in the qualitative study. The inter-
views were recorded and transcribed verbatim for
further analysis and field notes were recorded. Snowball
sampling was utilised until data saturation was achieved
in each site. Two data coders that were independent to
the interviewers undertook analysis using QSR NVivo 11
software (QRS, Vic, Australia). We used the framework
method with a coding framework that draws upon
the study objectives, logic model and interview guide
[16, 17]. New concepts initiated by participants that
could not be categorized within the initial scheme
were coded using an inductive approach and added to
the framework. The COnsolidated criteria for REport-
ing Qualitative research (COREQ) Checklist was used
to report the methodology and findings [18].
Results
Development of trial tools
We developed the training materials and data collection
tools based on the experiences of the previous CRADLE
projects [4, 5, 12–14]. It was necessary to create a training
package that could be disseminated quickly in multiple
contexts and easily understood by every cadre of HCP
with different resources available. Therefore, we selected
animated film as the main component so that voice overs
could be translated at minimal additional cost and it could
be disseminated widely onto smart phones by Bluetooth.
Feedback from end-users, health service managers and
implementation experts was incorporated.
We created a logic model to depict the components of
the intervention, how they may interact to produce
change and what the anticipated outcome of that change
may be (Fig. 1) [10, 19]. This was developed based on
the evidence described in the introduction with input of
the research team and key stakeholders. These included
representative healthcare professionals and service man-
agers from our low-income trial sites and implementa-
tion experts. The moderating factors and anticipated
changes to practice in the logic model were utilized to
inform the process evaluation outcome measures.
Feasibility of implementation
The intervention was implemented in three regional hos-
pitals, one from each site, together with 61 associated pri-
mary healthcare facilities. The proportion of staff trained
and the duration of training is shown in Table 3. In India
and Ethiopia, we translated the training materials and in
India the graphics of the poster and booklets were altered
to be more culturally appropriate. In all countries the
guidance for management of pre-eclampsia, haemorrhage
and shock, which was based on WHO guidelines [20, 21],
Table 2 Outcomes, method of measurement and time of measurement in the CRADLE-3 feasibility study
Outcome Method of Measurement Time of measurement
Feasibility Fidelity Duration of training At training
Dose Proportion of staff trained At training
Number of facilities included At training
Adaptations to fit context Observation of training At training
Understanding of training materials Questionnaires (n = 30 each site) Post training
Action Log of Clinical Practice (n = 30 each site) For 1 month post training
Acceptability Stakeholder Interviews (n = 5 each site) 3 months post implementation
Stakeholder Focus Group (n = 1 each site) 3 months post implementation
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was adapted to incorporate locally available resources and
infrastructure.
In total, 108 questionnaires were distributed and 97
fully completed by HCP and analysed, 16% by HCP
working in primary level facilities and 84% in secondary
level facilities. This represents 48% of those trained. Of
these, five were doctors, 78 were nurses and midwives
and 15 were allied HCP. The majority of respondents
had more than 5 years of service (1–5 years n = 28, 29%;
6–10 years n = 35, 36%; > 10 years n = 34, 35%). Results
indicated a good understanding use of the VSA and
interpretation of results with 73 participants (75%) scor-
ing more than 75% correct answers. HCP working in
secondary care scored higher in questions on how to act
in response to abnormal vital signs than HCP working
in primary care (74% (n = 60) scoring over 75% correct
compared to 56% (n = 9) of clinic participants.
Action logs were distributed to 90 HCP and completed
by 68 (76%). The level of detail completed was diverse
with many participants failing to complete details on
medication given or the time frame taken for action.
This was reported to be due to the additional burden of
work required to complete these logs and this is
explored further in the discussion. Analysis of these
records was therefore challenging and results should be
interpreted with caution. It was possible to determine
that in total, 62 red lights were recorded, indicating se-
verely abnormal vital signs. The majority (n = 50, 81%)
had optimal care appropriate for the available resources.
Of the 12 that did not, five were referred to hospital but
within a longer timeframe and seven were reported to
look well so no further action was taken.
The action logs demonstrated varying practice in
response to a yellow light with a downward pointing
arrow. This result indicates a relative low blood pressure
compared to the heart rate. In Ramadurg, India, the
majority of these patients were referred to higher level
care, compared to fewer in Bishoftu, Ethiopia. This vari-
ance highlighted ambiguity in the training materials.
This was explored widely with stakeholders and changes
made to the training materials accordingly. A yellow
down light may be caused by multiple clinical causes of
varying importance (such as maternal anaemia which
can be common in pregnancy) and therefore greater
emphasis was made on assessment of the patient’s clin-
ical condition in the final training materials.
Acceptability of the intervention and implementation
strategies
A total of 18 interviews and two focus group were under-
taken across the three sites in January and February 2016.
Fig. 1 Logic model for the CRADLE-3 intervention
Table 3 Fidelity and dose of implementation













21 90% (n = 92) 8 days 62
Bishoftu,
Ethiopia
3 85% (n = 37) 3 days 29
Ramadurg,
India
37 95% (n = 75) 2 days 53
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Participants were approached face to face and provided
written informed consent. The participants had limited
prior relationship with the researchers from training and
outreach support visits. Individual interviews were under-
taken with nine nurses, five midwives, one maternity
manager, two health assistants and one doctor. The me-
dian age of participants was 25–34 years (n = 12) (18–24,
n = 1; 34–44, n = 3; 45–54, n-2), the most common num-
ber of years of service was 1–5 (n = 8) (6–10 years, n = 5;
11–15 years, n = 2; > 15, n = 3). Findings are presented
under themes below. Interviews and focus groups were
undertaken in private, quiet locations near the partici-
pant’s place of work with no non-participant observers to
ensure confidentiality and allow for an open discussion.
Sessions lasted between 15 and 75 min and were
undertaken, translated and transcribed by experienced
local research coordinators (clinical background) fol-
lowing training from the trial coordinator and senior
social scientist (JS).
Use of CRADLE VSA in clinical decision making
It was widely reported that the CRADLE VSA package
improved capacity to make decisions about which women
require treatment and referral. This was true for HCP in
the community who initiated referral as well as those
working in facilities who initiated treatment or escalated
care to senior staff. The suggested reasons for this were
varied. HCP who were previously using auscultatory BP
devices reported lack of confidence in accurately aus-
cultating the Korotkoff sounds and therefore reported
regularly rounding the BP to the nearest ten or delaying
taking action. This was alleviated by the digital display
of systolic and diastolic blood pressure and pulse on
the CRADLE VSA.
“There, if we get high BP, we used to think and get the
BP checked by others, as we had less confidence in
that machine. We used to ask others saying that it has
shown high BP in our machine and we want to check
by you also. Here with this device (CRADLE VSA) we
can take decision immediately.” Staff Nurse, Hospital,
India
HCP also reported that the Early Warning System
alerted them to abnormalities in the results which may
otherwise not be recognised. This was reported to be
mainly because in pressured environments with fatigued
staff abnormal results may be missed whereas a red light
is an instantly recognisable alarm. This, in combination
with the training materials was felt to provide valuable
guidance in the action required to manage abnormalities.
The majority of HCP reported that this has improved the
time taken to recognise pregnancy complications and
initiate treatment or referral. These views are illustrated in
the quote below:
“Yes, more interventions are done and done in a more
prompt manner because of the indicators which one can
easily refer to and take action promptly. Interventions
are done early or immediately because of the indicators
that alert the clinicians. They are forced to act quickly
even if they refer, but they will have taken some action”
Staff Nurse Masvingo, Zimbabwe
Whilst the majority of HCP felt that the results are ac-
curate and the lights beneficial, there were two HCP
who reported that they did not always act on the lights
because they were confused. They felt that the yellow
light was reported too frequently when patients ap-
peared well. The quote below demonstrates this:
“But what we are observing is that for majority of
women it is showing yellow with down arrow. But the
patient is stable, normal, she is not sick and she is
well. In such situations we feel “why it so? The woman
is normal, but still why it is showing yellow down”?”
Staff nurse, PHC, India.
Other HCP acknowledged that this was a common re-
sult but demonstrated understanding of potential causes
and how to manage this result. This finding triangulates
the results of the Action Log and is explored further in
the discussion.
Aid of the CRADLE VSA in escalating care and referral
Nursing HCP reported that when they were previously
using auscultatory devices they reported doubt or being
challenged when referring cases to medical staff. The
improved confidence in the vital signs measurement and
the understanding conveyed by the training package was
beneficial in escalating care to senior staff. This was also
true in convincing women and their families of the need
for further monitoring or referral.
“It is helpful in providing immediate care to the
patient. As everything is given there (booklets and
poster) like the patient has to be referred within 4
hours or within 1 week...etc., we call the attenders and
convince them, to refer the patient at the earliest.”
Staff Nurse, Gokak, India
The majority of HCP reported an increase in the num-
ber of vital sign abnormalities detected; however, the
reported impact on the rate of referrals varied between
countries. All participants from India reported an increase
in the number of referrals. The number of hypertensive
patients referred was increased as mild hypertension was
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considered more seriously. The number of patients with
low blood pressure detected and referred was also
noted to increase. In Zimbabwe and Ethiopia responses
were mixed with some reporting a reduction in referrals
due to improved understanding of vital signs and confi-
dence in initiating treatment peripherally. A quote to
illustrate this is:
“because of the indicators the referrals have
decreased, now we know when to refer and we now
don’t refer all patients for the sake of referring.”
Nurse, Clinic, Zimbabwe
Use of results to finalise implementation strategies
The MRC Guidance and supporting documents high-
light that the pilot data should be used to shape the
intervention and implementation strategies. Following
the completion of this feasibility study, the experiences
of implementation and input from a stakeholder meeting
across all sites in February 2016 were used to agree a
number of changes prior to the main trial. The choice of
implementation strategy was guided by the Expert
Recommendations for Implementing Change project [9]
with the aim of improving understanding of the training
materials and overcoming identified barriers to use.
Table 4 presents the key issues experienced through the
feasibility study alongside quotes to support this and the
implementation strategies or changes we have selected.
A key implementation strategy that we selected as a
result of the feasibility findings was the identification
and training of CRADLE champions. These are clinical
staff and local leaders who receive more in-depth train-
ing about device and are equipped with the tools to
support the use of the VSA in their area. Whilst we
wanted the trial to remain pragmatic and replicable, this
strategy was chosen to support ongoing local training
and build local capacity for maintenance. The import-
ance of the support of the implementation team on the
effectiveness of the intervention was also noted during
the study and added to the logic model as a core compo-
nent of the intervention. In order to maintain the prag-
matic trial design, it was decided not to quantify this
support but for the research team to observe it during
the routine monthly site monitoring and be aware of its
potential impact.
Main trial primary outcomes
As the main trial has a stepped wedge design with an
intervention incorporated into routine care, cluster level
consent instead of individual was appropriate. This was
agreed as preferable by all sites during the development
work. All ten trial sites gained ethical and local approval
for participation in the main trial. Nine of them achieved
this before or during the feasibility phase and were
therefore able to commence data collection, with six
sites completing a full 3 months of data collection.
During this formative phase a total of 844 outcome
Table 4 Barriers to measuring the vital signs and using the VSA and actions made prior to the main trial
Issue from Feasibility study Supporting quotes from Interviews and Focus Group Changes required after feasibility study
Understanding of yellow light
with down arrow
“When the pregnant woman comes to us she is well
and it shows yellow down (laughs); in that case how
to interpret?” Staff Nurse, India
- Training materials updated to explain the reason
for each colour light.
- Guidance updated to place greater emphasis on
how to assess the woman to decide if further
action or referral is required.
Problems with charging the
VSA
“… some workers say that the battery life is good but
I have to charge it for daily. If I have to go for BP
check-up today I have to charge it first.” Staff Nurse,
India
- Interactive training session developed which
incorporates guidance on charging and
accountability for charging.
- Including explanation that more than 100 readings
can be taken even when the battery low sign is
showing and overcharging will damage the
battery.
Provision of Charger “the package should include the charger rather than
USB cable only so that we can charge it easily” Staff
Nurse, Zimbabwe
Chargers provided in addition to the cable that
comes as standard in the package.
High staff turnover / incapacity
to train all staff at once
“Initially, we faced difficulty. There were nurses using it
during the night shift and they were not trained.” Staff
Nurse, Bishoftu
Designated CRADLE Champions in each facility
identified to provide ongoing local training and
support for CRADLE VSA
Unsupportive seniors “Recently during an ANC clinic he inquired which
device we are using; we said “we are using the
CRADLE device given by the research unit” then he
said “oh… it shows yellow down to all pregnant
women, so better do not use it”.” SN, India
- Designated CRADLE Champions identified to
provide ongoing local training and support for
CRADLE VSA
- Engage Local Opinion leaders prior to
implementation
Need for equipment “…no BP machines at all, the one we had was no
longer working.” Staff Nurse, Zimbabwe
Ensure adequate supply of VSA available
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events (any one of eclampsia, maternal death, hysterec-
tomy, ICU admission or stroke) occurred in 681 women
from nine of the ten sites. On average, the number of
women experiencing events each month varied from five
in Gokak, India to 63 in Zomba and South-Eastern
Malawi (median 19.6, standard deviation 19.6). The most
common outcome was eclampsia (n = 386, 46%) followed
by ICU admission (n = 271, 32%), hysterectomy and
maternal death (n = 96, 11%; n = 91, 11% respectively)
and stroke (n = 2, 0.2%). The tools for data collection
were found to be appropriate. Methods of data collec-
tion were discussed and optimised based on the existing
resources available in each site. Outcomes were triangu-
lated across multiple sources (including referral registers,
ward registers, patient records, local mortality and morbid-
ity records, active case finding) to ensure data completeness
and all outcomes checked to avoid double counting.
These outcomes had been intended as unequivocal
markers of severe maternal mortality and morbidity.
However, during the process of data collection it became
apparent that ICU admission was dependent on avail-
ability of services which varied greatly between clusters
and therefore this was not a reliable proxy marker of
maternal morbidity. The number of strokes reported
across all sites was just two, both from one site. It was
therefore prospectively decided that for the main trial
the composite primary outcome would include only
eclampsia, maternal death and emergency hysterectomy.
Given that the size of clusters varies greatly, it was
agreed that the number of deliveries would be counted
as a surrogate denominator so that results for the main
trial could be presented as an event rate per 10,000
deliveries. These prospective amendments were added to
the trial registry (ISRCTN41244132).
Randomisation and power calculation
An estimated event rate from the data was used to
inform the randomisation sequence and power calcula-
tion of the main trial. With so few centres to be rando-
mised there was a risk of unbalance – for example that
by chance the centres with the highest event rates might
be allocated to the intervention at the end of the study,
giving a false impression of a low event rate in centres
which received the intervention early, and hence a
biased estimate of the treatment effect. Although the
planned analysis would correct for this, to further
minimize the problem, a restricted form of randomisa-
tion was used, so that the rank correlation between the
initial event rate, and the order of randomisation was
zero. For logistic reasons, the two centres outside Africa:
Cap Hatien (Haiti) and Gokak (India) were treated as
one centre for randomisation (but not for analysis).
First the overall rate of the primary outcome was deter-
mined in the nine clusters and each cluster given a
corresponding rank r between 1 and 9. Then a provisional
list l of the order of intervention was determined for each
cluster using computer-generated random numbers based
on an arbitrary random number seed. Spearman’s rank cor-
relation rho between r and l was determined. If the rank
correlation was not equal to 0, the list was discarded, and
the process repeated until an acceptable order was deter-
mined. The first acceptable randomly-generated list was
retained. This resulted in a near-zero Pearson’s product-
moment correlation of − 0.019 between the event rate and
the order of randomisation.
Based on these data, our sample size estimation was
carried out by the trial statistician, using Stata version
13.1 and the methods of Hemming and Girling [22]. For
the purpose of the power calculation, an assumption that
there are at least 4000 deliveries per cluster per month
was made (or 8000 per cluster period of 2 months) and
at least nine clusters, each observed for 20 months (ten
time periods of 2 months each). Our feasibility data indi-
cated a baseline event rate of 1% and we have antici-
pated a 25% reduction in this to 0.75% post intervention.
We would require a total of 2450 outcome events with a
coefficient of variation of 0.4 and an Intra Cluster
Correlation of 0.0085, to have power of 95%.
Discussion
This paper aims to describe the mixed methodology
feasibility study exploring the acceptability and feasibility
of introducing the CRADLE package into routine mater-
nity care in LMIC along with the feasibility of the main
trial data collection processes. The key findings are that
the intervention can be delivered with high fidelity and
dose and incorporated into routine maternity care
successfully in different contexts without major adapta-
tion. In addition, we have confirmed that the methods of
collecting the main outcome data are feasible and can be
maintained for consistency and this data has successfully
been used to improve the study design, randomisation
and power calculation.
The MRC framework stresses the importance of
quality development work to avoid problems with
acceptability, compliance, recruitment and retention.
Yet methodological research suggests that pilot studies
are often poorly performed and few are published [23].
Most published examples of complex interventions
demonstrate valuable learning from pilots; for ex-
ample, the exploratory RCT of an intervention to re-
duce alcohol related harm demonstrated that whilst
the trial was methodologically feasible, poor enthusi-
asm resulted in low fidelity thus the conclusion that
the intervention would need to be enforced in future
work [24]. However, published description of its use in
the field of maternity and in LMIC is scarce.
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One key learning from our feasibility study was the
practicalities of a pragmatic process evaluation in a low-
resource setting. The MRC supporting guidance provides
explanation for each of the key dimensions of implemen-
tation that could be measured and guides researchers to
select the most important questions to investigate. Whilst
this is a strength of the framework as it ensures compre-
hensive evaluation of implementation, it provides little
guidance on how to select suitable outcome measures for
each dimension. This is especially challenging when work-
ing in a resource-poor environment with additional
burden of high workload and heterogeneous routine data
collection. In this feasibility study, measuring multiple
components compared to baseline was not possible within
the short time frame. The proportion of people trained
centrally and time taken for training were selected as
simple surrogates of fidelity and dose. However, in the
qualitative work the majority of HCP reported the VSA
was easy to use and it was possible to commence use just
on reading the training materials so the extent that these
measures may impact the effectiveness of the program is
unknown. In the main trial the number of core compo-
nents delivered in training and how they were adapted to
context were added to the measure of fidelity.
The MRC Guidance advises using the logic model to
identify causal assumptions and guide selection of research
questions. In the CRADLE Logic model the assumed
changes to practice include improving access to equipment
therefore in the trial we will capture the proportion of HCP
that have access to a working BP machine before and after
implementation. A further assumed change is improving
vital sign measurement and management of complications.
In this feasibility study, the action log of referral practice
was poorly received and completed due to the extra burden
of work it demanded. For the main trial, we chose to
explore change in practice during the qualitative work ra-
ther than during structured observation due to the large
variety of normal practice in different countries. The quali-
tative work also highlighted that number of women referred
to higher level care was a potential key moderator. There-
fore, after stakeholder discussion across our sites we agreed
to measure the proportion of women presenting for mater-
nity care that had their blood pressure measured and the
proportion that were referred to higher level care. Due to
the intensity of this data collection it was agreed this would
be measured for a period of 4 weeks before implementation
and 4 weeks, 3 months after the device was introduced to
allow time for familiarization of the VSA in routine mater-
nity care. We found the process of identifying potential
factors that may impact on the success of the trial and tai-
loring outcome measures accordingly was achievable for a
team of predominantly newcomers to the field of imple-
mentation. It was also beneficial in assuring that assump-
tions are shared between stakeholders.
Strengths and limitations of the study
We describe the feasibility testing of the CRADLE inter-
vention prior to a fully powered trial. This was guided
by the MRC guidance and was undertaken over a
6-month period; results are therefore applicable to
others working in restricted funding periods. Feasibility
and pilot research is often skipped or inadequate to fully
inform the main trial and rarely published to inform
others researching similar areas. In a situation where a
complete development phase is not possible due to the
stepped wedge design we demonstrated that our event
rate in the main trial sites is sufficient to have adequate
power. We undertook formal qualitative analysis to
explore the acceptability of the program components
and feasibility of implementation. We did not collect
cost-effectiveness data in the feasibility study but will
collect this data for an economic evaluation in the full
trial. We did not assess knowledge of vital signs meas-
urement prior to training and therefore results should
be interpreted with caution.
Conclusions
This feasibility study demonstrates that the components of
the intervention were acceptable and the methods of imple-
menting successful. Qualitative work identified key modera-
tors that have informed the main trial process evaluation.
Changes to the training package, implementation strategy,
study design and processes were identified to optimize the
main trial implementation. Carrying out these changes in
practice, (for example to the data collection forms, database
and graphics of the training materials were challenging)
within the six-month allocated time frame of this feasibility
study. If larger changes had been required, for example to
the components of the intervention which would require
re-testing, this would not have been possible. Funders
recommending that a development phase is incorporated
into a standard 3-year funding period might therefore take
into consideration the time taken to undertake the work,
analyse results and incorporate changes into the study to
ensuring meaningful improvements can be made.
Concurrently assessing the feasibility of the trial out-
comes in the 10 main trial sites and the implementation
processes in geographically distant sites was necessary
to avoid contamination of the trial area. Whilst under-
taking this in multiple sites required additional work, it
allowed for greater understanding of how the interven-
tion could be adapted in each context and how the
main trial will run. The MRC Guidance and supporting
documents provided a valuable tool to guide the overall
design of this study and the development of the process
evaluation for the main trial. This study presents a real
world worked example that has utilised this guidance
to refine the intervention, main trial outcomes and
process measures.
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